Search results
Dr. David M. Hyman is an oncologist in New York, New York and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Weill Cornell Medicine and...
- New York, NY
- 12.2B
Jun 3, 2017 · Dr. David Hyman, MD. Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American ...
Nov 26, 2018 · “With this drug, we are seeing the true potential of precision oncology come to life,” says David Hyman, Chief of the Early Drug Development Service at Memorial Sloan Kettering. Dr. Hyman is the senior author of a study published in the New England Journal of Medicine (NEJM) in February on the effectiveness of the drug.
David M. Hyman, MD, is the Chief of the Early Drug Development Service and Co-Chair of the Center for Mechanism Based Therapy (CMBT) at Memorial Sloan Kettering Cancer Center in New York City, as well as a senior editor for Clinical Cancer Research.
Medical Oncology* • Male • Age 44. Dr. David Hyman, MD is a medical oncology specialist in New York, NY and has over 17 years of experience in the medical field. He graduated from Cornell University in 2006. He is affiliated with Memorial Sloan Kettering Cancer Center. He is accepting new patients.
- 1275 York Ave, New York, 10065, NY
Apr 1, 2019 · On April 1, 2019, at the annual meeting of the American Association for Cancer Research, an international team of researchers led by Memorial Sloan Kettering’s David Hyman presented results from the first phase I clinical trial of a related drug, LOXO-195 (also called BAY 2731954).
Mar 1, 2015 · To explain the latest findings, Dr. David Hyman from the Memorial Sloan Kettering Cancer Center joins Hari Sreenivasan. Read the Full Transcript. HARI SREENIVASAN: Some cutting-edge...
